UCB (OTCMKTS:UCBJF) Shares Gap Up – Here’s Why

UCB SA (OTCMKTS:UCBJF) gapped up before the market opened on Friday . The stock had previously closed at $284.2414, but opened at $297.4480. UCB shares last traded at $297.4480, with a volume of 135 shares.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on UCBJF. The Goldman Sachs Group restated a “buy” rating on shares of UCB in a research report on Monday, February 16th. Wolfe Research began coverage on shares of UCB in a research report on Monday, February 23rd. They issued an “outperform” rating for the company. Six research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, UCB currently has an average rating of “Buy”.

UCB Price Performance

The company has a debt-to-equity ratio of 0.33, a current ratio of 1.19 and a quick ratio of 0.78. The stock’s 50-day moving average is $294.91 and its 200 day moving average is $297.56.

About UCB

UCB SA is a Belgium-based biopharmaceutical company focused on the discovery, development and commercialization of treatments for severe diseases of the immune system and the central nervous system. Founded in 1928 as Union Chimique Belge, the company transitioned from chemicals into pharmaceuticals and biologics and today concentrates its efforts on specialty medicines and research-driven innovation. UCB’s work spans small molecules and biologics, with an emphasis on improving outcomes for patients with chronic and complex conditions.

Key therapeutic areas for UCB include immunology and neurology, where the company markets several well-known products and maintains an active clinical pipeline.